SB 239063

SB 239063 is a selective p38 MAPK inhibitor (IC50 = 44 nM for recombinant purified p38alpha). It displays greater than 220-fold selectivity for p38 MAPK over ERK, JNK1, and other kinases. SB 239063 has been shown to reduce inflammatory cytokine production in lipopolysaccharide-stimulated human peripheral blood monocytes (IC50s = 0.12 and 0.35 µM, respectively for IL-1 and TNF-alpha) and is neuroprotective following oral administration in a rat model of cerebral focal ischemia.Formal Name: trans-4-[4-(4-fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)-1H-imidazol-1-yl]-cyclohexanol. CAS Number: 193551-21-2. Molecular Formula: C20H21FN4O2. Formula Weight: 368.4. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 10 mg/ml, DMSO: 16 mg/ml, DMSO:PBS (pH 7.2) (1:6): 0.14 mg/ml, Ethanol: 0.25 mg/ml. lambdamax: 232, 268, 317 nm. SMILES: O[C@@H](CC1)CC[C@H]1N2C(C3=CC=NC(OC)=N3)=C(C4=CC=C(F)C=C4)N=C2. InChi Code: InChI=1S/C20H21FN4O2/c1-27-20-22-11-10-17(24-20)19-18(13-2-4-14(21)5-3-13)23-12-25(19)15-6-8-16(26)9-7-15/h2-5,10-12,15-16,26H,6-9H2,1H3/t15-,16-. InChi Key: ZQUSFAUAYSEREK-WKILWMFISA-N.